secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001628280-23-015219
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q1 revenue $105.7M (+13% YoY); raises FY2023 guidance to $435-455M
--------------------------------------------------------------------------

- Revenue $105.7M vs $93.7M Q1 2022; net income $15.9M ($0.14 diluted EPS) vs $22.8M ($0.20) YoY.
- Raised 2023 revenue guidance to $435-455M from prior $430-450M.
- Cash and investments $465.1M at March 31, 2023; repurchased 6.6M shares for $145.4M in April 2023.
- Operating expenses rose to $90.8M from $66.9M on increased clinical trial and commercial spending.
- NDA submission for relacorilant in Cushing's syndrome planned first half 2024; Phase 3 GRACE enrollment near completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828023015219/0001628280-23-015219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828023015219/cort-20230503.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-015219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer